Multimodal Evidence of Cognitive Restoration in Alzheimer’s Disease Following Biophoton Therapy: A Neurophysiological and Energetic Assessment

Authors

  • James Z Liu First Institute of All Medicines, 139 Pittsburg Road, Butler, PA 16001, USA Author
  • Mariola A Smotrys First Institute of All Medicines, 139 Pittsburg Road, Butler, PA 16001, USA, Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA Author
  • Seth D Robinson Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA Author
  • Hui X Yu Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA Author
  • Sherry X Liu Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA Author
  • Devin R Liu Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA Author
  • Helen Y Gu First Institute of All Medicines, 139 Pittsburg Road, Butler, PA 16001, USA, Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA Author

Keywords:

Alzheimer’s Disease, Biophoton Therapy, Quantitative EEG, Event-Related Potentials, Brain Energy Mapping, Non- Linear Scanning diagnostics, Neurocognitive Rehabilitation, Vascular Diagnostics, Neurotherapy

Abstract

Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder marked by cognitive decline, memory loss, and functional impairment. While pharmacologic treatments offer limited symptomatic relief, there is a growing need for non-invasive approaches that promote neurophysiological restoration. Biophoton therapy, a modality using low-level electromagnetic emissions to stimulate biological systems—has shown potential in enhancing brain function.

Objective: This study aimed to evaluate cognitive improvements in AD patients following biophoton therapy using a multimodal set of objective
neurophysiological and energetic measurement tools.

Methods: A cohort of AD patients underwent biophoton therapy for 2 to 4 weeks. Clinical effects were assessed through quantitative electroencephalography (qEEG) and event-related potentials (ERP) using the BrainView Neurotherapy Platform. Additional objective evaluations included 3D Non-Linear Scanning Diagnostics (3D-NLS) for energetic brain mapping, the Bio-Well GDV Camera 3.0 for electromagnetic field coherence, and the FALCON/QUAD Express Doppler ultrasound system to assess vascular health. Data were collected at baseline and at regular intervals to monitor changes in attention, working memory, and cortical activation patterns.

Results: A clinical study demonstrated that biophoton therapy led to significant cognitive improvement within 4 weeks in patients with moderate to severe Alzheimer’s disease. qEEG revealed significant increases in posterior peak frequencies and reductions in theta/beta ratios, indicating improved attentional control and cortical activation. ERP latency (N400) decreased, suggesting faster cognitive processing. Frontal alpha asymmetry shifted toward a balanced or positive profile, reflective of mood stabilization. 3D-NLS imaging showed a reduction in compensatory burdens and complete resolution of nidus of defeat zones. Bio-Well analysis indicated increased systemic energy coherence, while vascular assessments demonstrated improved arterial elasticity and cerebral circulation.

Conclusion: Biophoton therapy was associated with measurable improvements in cognitive and emotional biomarkers in patients with Alzheimer’s disease. The use of multiple objective assessment tools, including electrophysiological, energetic, and vascular measures—validates these clinical findings and supports further investigation into biophoton therapy as a non-invasive modality for neurocognitive rehabilitation.

Author Biography

  • James Z Liu, First Institute of All Medicines, 139 Pittsburg Road, Butler, PA 16001, USA

    James Z Liu, First Institute of All Medicines, 139 Pittsburg Road, Butler, PA 16001, USA, Tesla BioHealing, Inc. 111 McCoy Street, Milford, USA.

Downloads

Published

2025-07-28

Issue

Vol. 2 No. 3 (2025): Volume 2 Issue 3

Section

Articles